HASBSB146 ODOMD 4001
SENATE SUMMARY OF HOUSE AMENDMENTS
SB 146 2022 Regular Session Talbot
KEYWORD AND SUMMARY AS RETURNED TO THE SENATE
HEALTH/ACC INSURANCE. Provides for health insurance coverage of cancer
treatments (8/1/22)
SUMMARY OF HOUSE AMENDMENTS TO THE SENATE BILL
1. Changes "may" to "shall" to reflect the intentions of proposed law.
DIGEST OF THE SENATE BILL AS RETURNED TO THE SENATE
DIGEST
SB 146 Engrossed 2022 Regular Session Talbot
Present law prohibits a health coverage plan from denying coverage for the treatment of
metastatic or unresectable tumors with a medically necessary drug prescribed by a physician
on the basis that the drug is not indicated for the location in the body of the patient's cancer,
if the drug is approved by the U.S. Food and Drug Administration (FDA) for the treatment
of the specific mutation of the patient's cancer. Provides that coverage may be denied if an
alternative treatment has proven to be more effective in published randomized clinical trials
and such treatment is not contraindicated in the patient. Proposed law retains the present law
prohibition but applies it to the treatment of other advanced cancers.
Proposed law prohibits denial of coverage on the basis that the medically necessary drug is
not indicated for a specific tumor type. Further prohibits an insurer from considering the
treatment as experimental or outside of its policy scope if the FDA has approved the drug
for the treatment of cancer with the specific genetic mutation, even if the treatment is for a
different type of tumor.
(Amends R.S. 22:1054.1(A))
______________________
Thomas L. Tyler
Senate Counsel